Gujarat Terce Laboratories Limited ka detailed fundamental analysis niche diya gaya hai. Ye analysis today’s latest price (06 Feb 2026) aur latest Q3 FY26 results (declared on 04 Feb 2026) ke basis par taiyar kiya gaya hai.
📑 Gujarat Terce Laboratories Limited – Stock Analysis Report
1️⃣ Business Model & Work
Company Kya Karti Hai?
Gujarat Terce Laboratories ek Pharmaceutical Formulations company hai jo medicines manufacture aur market karti hai. Ye ‘Branded Generics’ segment me operate karti hai.
- Core Business: Tablets, Capsules, Syrups, aur Injections banana.
- Key Brands: Company ke paas 70+ brands hain. Kuch popular brands hain:
- Acolate (Respiratory)
- Tynol (Pain relief)
- Aziter (Antibiotic)
- Presence: Inka business majorly 13 states me hai (North & West India strong focus) aur inke network me 1000+ distributors hain.
- Manufacturing: Inki unit Chhatral, Gujarat me hai.
2️⃣ Industry & Sector Analysis
- Sector: Pharmaceuticals (Micro-cap).
- Status: Defensive but Competitive. Indian domestic pharma market grow kar raha hai, lekin choti companies ke liye regulatory compliance aur raw material cost (API prices) sabse bada challenge hai.
- Shift: Industry ab “Volume” se “Value” ki taraf move kar rahi hai. Gujarat Terce bhi yahi koshish kar rahi hai (Low margin products band karke high margin par focus).
3️⃣ Latest Financial Performance (STRICT DATA RULE)
Current Market Price (CMP): ₹44.25 (Approx)
Market Cap: ~₹34 Cr (Micro-cap)
⚠️ Note: Niche diye gaye figures Latest Q3 FY26 (Dec 2025) result par based hain jo 04 Feb 2026 ko announce hua hai.
| Metric | FY 2024 (Mar) | FY 2025 (Mar) | Q3 FY25 (Dec 24) | Latest Q3 FY26 (Dec 25) |
| Revenue (Cr) | ₹46.78 | ₹50.19 | ₹12.68 | ₹12.29 (Down 3% YoY) |
| Net Profit (Cr) | (₹0.98) | (₹3.39) | ₹1.00 | ₹0.76 (Down 24%) |
| EBITDA (Cr) | N/A | N/A | ₹1.15 | ₹1.25 (Up 8%) |
| EBITDA Margin | N/A | N/A | 9.13% | 10.16% (Improved) |
| EPS (₹) | -1.31 | -4.57 | 1.36 | 0.95 |
| Debt/Equity | Low | Low | – | Low |
Key Observations (Latest Result Analysis):
- Revenue Dip: Sales me 3% ki girawat aayi hai. Management ka kehna hai ki unhone jaanbujhkar “Low-Margin” products ki sales band ki hai taaki profitability badhai ja sake.
- Margin Expansion: Revenue girne ke bawajood, EBITDA (Operating Profit) 8% badha hai aur margins 9.1% se badhkar 10.1% ho gaye hain. Ye ek positive sign hai ki company efficiency par kaam kar rahi hai.
- Profit Down: Net Profit girne ka karan depreciation ya tax adjustments ho sakte hain, lekin core business (EBITDA level) par company ne perform kiya hai.
4️⃣ Management & Shareholding (Latest Verified)
- Promoter Holding (40.03%): 🟢 POSITIVE SIGNAL.
- Recently Promoters ne Warrants convert karke apna stake 37.03% se badhakar 40.03% kar liya hai (Dec 2025 me).
- Jab promoter market rate ya usse upar paisa lagakar stake badhaye, to ye confidence ka sabse bada saboot hai.
- FII / DII Holding (0%): Koi institutional holding nahi hai (Micro-cap hone ki wajah se normal hai).
- Public Holding (~60%): Major stake retail investors ke paas hai.
5️⃣ Valuation (Latest Market Data)
- PE Ratio: ~12.2x (Based on annualized FY26 Est EPS of ~₹3.6).
- Price to Book (PB): ~4.3x.
- Valuation Check:
- Industry PE (Pharma) usually 25-30x hota hai. Ye stock 12x PE par mil raha hai, jo “Cheap” dikhta hai.
- Lekin ye cheap valuation “Negative Growth” (Sales down) ki wajah se hai. Market tab tak re-rate nahi karega jab tak sales wapas grow na kare.
6️⃣ Future Growth Triggers (3–5 Years)
- Product Mix Change: Company purane, kam munafay wale products ko hata kar naye high-margin products launch kar rahi hai. Agar ye strategy kaam kar gayi, to agle 2 saal me profit multiply ho sakta hai.
- Geographical Expansion: Company North India se nikal kar South aur East India me enter karne ka plan bana rahi hai.
- Promoter Betting: Promoters ka paisa lagana (Warrants ke through) indicate karta hai ki agle 1-2 saal me company kuch bada plan kar rahi hai.
7️⃣ Present Situation (Outlook)
- Current Phase: “Consolidation & Cleanup”. Company abhi safai abhiyan me hai (bad business out, good business in). Financials mixed hain (Sales down, Margins up).
- Momentum: Stock price stable hai, result ke baad koi bada crash nahi aaya, jo dikhata hai ki market ne weak numbers ko digest kar liya hai.
8️⃣ Risk & Red Flags ⚠️
- Micro-Cap Risk: Market Cap sirf ₹34 Cr hai. Liquidity bahut kam hoti hai. Buy/Sell orders execute hone me dikkat aa sakti hai.
- Revenue Degrowth: Agar agle 2 quarters tak sales aise hi girti rahi, to fixed costs cover karna mushkil ho jayega aur company wapas loss me ja sakti hai.
- Dependency: Company sirf domestic branded generics par dependent hai, jahan competition bahut intense hai.
9️⃣ Final Verdict
- Summary: Gujarat Terce Laboratories ek Classic Micro-Cap Turnaround Story hai. Financials perfect nahi hain (Revenue gir raha hai), lekin Promoters ka stake badhana aur Margins ka improve hona ache sanket hain. Valuation sasta hai (12x PE), lekin risk bahut zyada hai.
- For Conservative Investors: AVOID. Micro-cap aur unstable earnings aapke liye suitable nahi hain.
- For Aggressive Investors: Watchlist / Small Buy. Ye stock current price par ek “Value Bet” ho sakta hai. Promoters ka confidence dekhkar ek chota allocation (High Risk capital) consider kiya ja sakta hai, lekin view kam se kam 2 saal ka hona chahiye.
- Target Range: Agar EPS ₹4 tak pahunchta hai (FY27 exp), to stock ₹60-70 range me ja sakta hai.
- Risk: Downside risk ₹30-35 tak hai agar losses wapas aaye.
Disclaimer: Ye article sirf educational purpose ke liye hai. Kisi bhi nivesh se pehle apne Financial Advisor se salah zarur lein.